Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Sorbonne Université

Université Pierre Et Marie Curie (paris 6)

Université De Paris

Université Paris Descartes

Université Pierre Et Marie Curie

Matthieu Sollogoub

Vincent Calvez

Anne-Geneviève Marcelin

Laurent Bouteiller

Dmitri Colesnic

Julien Rossignol

Melanie Etheve-Quelquejeu

Pierre Evenou

Cathia Soulie

Mickaël Menand

Adélie Gothland

Mélanie Etheve-Quelquejeu

Anne-Genevieve Marcelin

Mickael Menand

Adelie Gothland

The invention relates to a capped cyclodextrin-hydrophobic moiety conjugate, to a supramolecular polymer formed of capped cyclodextrin-hydrophobic moiety conjugates according to the invention and to a siRNA-cyclodextrin complex comprising a supramolecular polymer according to the invention. The invention also relates to a method for manufacturing the capped cyclodextrin-hydrophobic moiety conjugate, the supramolecular polymer, the siRNA-cyclodextrin complex according to the invention. The capped cyclodextrin-hydrophobic moiety conjugate of the invention comprises a capped cyclodextrin group and at least one hydrophobic moiety bound by a first linker to one of the carbon atoms of the cap. The invention can be used for various applications in particular in the pharmaceutical field.

Capped cyclodextrin-hydrophobic moiety conjugate, cyclodextrin supramolecular polymer, and cyclodextrin-siRNA complex and method of synthesis thereof

The present invention describes the use of nucleoside analogs for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogs, and a method for evaluating the sensitivity to said treatment.

Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment

Growing community of inventors

Paris, France

Matthieu Sollogoub